Sleep and mental health are intertwined in ways that are poorly understood by most people who struggle with both — and by some healthcare providers who treat each in isolation. The dominant narrative for decades was that poor sleep is a symptom of mental health disorders: depression causes insomnia, anxiety causes sleep disruption, and if you treat the underlying condition, sleep improves. That model isn't wrong, exactly, but it's incomplete enough to cause real treatment failures.
The current evidence, supported by research from sleep medicine and psychiatry alike, supports a bidirectional model: poor sleep worsens and perpetuates psychiatric conditions, and psychiatric conditions worsen sleep. When both are present simultaneously — which is extremely common — treating only one without addressing the other produces suboptimal outcomes. This article explains the clinical picture and what psychiatry can offer.
Insomnia as a diagnosis, not just a complaint
Insomnia disorder (ICD-10 G47.00) is defined by the DSM-5-TR as dissatisfaction with sleep quantity or quality, with difficulty initiating sleep, staying asleep, or early-morning awakening and inability to return to sleep — occurring at least three nights per week for at least three months, causing clinically significant distress or functional impairment, despite adequate opportunity for sleep. That last clause matters: insomnia is not inadequate sleep opportunity (a person working two jobs with a 4 AM wakeup time doesn't have insomnia disorder, they have inadequate sleep time). Insomnia is difficulty with sleep when conditions for sleep are available.
Insomnia is common — population estimates suggest roughly 10–15% of adults meet criteria for chronic insomnia disorder, with another 20–30% having significant but subthreshold sleep complaints. It's also one of the most undertreated conditions relative to its prevalence and impact, in part because patients frequently mention it to providers as a secondary complaint and providers focus on the primary diagnosis.
The mental health connection: which conditions are most affected?
The relationship between insomnia and psychiatric illness is present across multiple diagnoses, but the specific profile varies.
Depression: Insomnia and depression have a well-documented bidirectional relationship. Insomnia is a risk factor for developing depression; meta-analyses have found that people with chronic insomnia have approximately twice the risk of developing a depressive episode compared to good sleepers. Conversely, insomnia is among the most common residual symptoms after depression treatment — an important point, because residual insomnia after antidepressant treatment significantly increases the risk of depressive relapse. Treating the insomnia as part of depression treatment, rather than waiting for it to resolve secondarily, is supported by the evidence.
Anxiety: Anxiety and insomnia share a common mechanism: hyperarousal. The physiological arousal of the stress response — elevated cortisol, increased sympathetic nervous system activity, hypervigilance — is incompatible with the relaxation required to initiate and maintain sleep. Generalized anxiety disorder and PTSD are particularly associated with chronic insomnia, with the intrusive cognitive activity of worry and trauma-related arousal driving the sleep disruption.
Bipolar disorder: Sleep disruption is both a symptom and a trigger in bipolar disorder. Decreased need for sleep (as distinct from insomnia — the ability to sleep but not feeling the need to) is a core feature of manic and hypomanic episodes. Circadian rhythm disruption — irregular sleep timing — is a risk factor for mood episode triggering in bipolar disorder. For this population, sleep regularity is a legitimate clinical target.
ADHD: Sleep disturbances are more prevalent in adults with ADHD than in the general population. The mechanisms are multiple: delayed circadian phase (later natural sleep timing), difficulty with the behavioral routine of sleep initiation, and stimulant medication timing effects if taken too late in the day. ADHD and insomnia presenting together require a treatment approach that addresses both.
CBT-I: the evidence-based first-line treatment
Cognitive Behavioral Therapy for Insomnia (CBT-I) is endorsed by the American College of Physicians and the American Academy of Sleep Medicine as the first-line treatment for chronic insomnia — ahead of medication — in adults. This is not a minor clinical recommendation: CBT-I produces durable improvements in sleep onset latency, wake time after sleep onset, and sleep efficiency, and unlike medication, those improvements are maintained after treatment ends.
CBT-I has several components: sleep restriction therapy (temporarily consolidating sleep to increase sleep pressure), stimulus control (rebuilding the association between bed and sleep), cognitive restructuring (addressing the unhelpful beliefs about sleep that perpetuate insomnia), and sleep hygiene education. The specific techniques counterintuitive: sleep restriction, for instance, initially allows less time in bed, which feels worse before it gets better, but it's among the most powerful components of CBT-I.
CBT-I delivered via telehealth — either through synchronous video sessions or digital platforms — has shown efficacy comparable to in-person delivery. Digital CBT-I programs are now widely available and represent an accessible entry point, particularly for people whose insomnia is less severe or who prefer self-guided approaches.
Where medications fit in psychiatric insomnia management
Medication is a legitimate option for insomnia, particularly when insomnia is severe, when CBT-I alone hasn't been sufficient, or when a short-term bridging approach is needed while behavioral therapy takes effect. But medication for insomnia warrants careful prescribing, and a responsible psychiatrist will discuss the trade-offs with you rather than defaulting to a prescription.
Several medication options have FDA approval for insomnia. Doxepin at low doses (3–6mg, as Silenor) is FDA-approved for sleep maintenance insomnia; at these doses, it acts primarily as a histamine antagonist with minimal antidepressant effect and a favorable safety profile. Suvorexant (Belsomra) and lemborexant (Dayvigo) are orexin receptor antagonists — a mechanistically distinct class that works by blocking the wake-promoting orexin system rather than sedating the overall brain; they have a favorable safety profile compared to older sedative-hypnotics. Eszopiclone, zolpidem, and zaleplon are non-benzodiazepine GABA-A receptor modulators (sometimes called "Z-drugs") with FDA approval for insomnia; they are Schedule IV controlled substances and carry dependence risk with long-term use.
We're not saying sleep medications are harmful — we're saying that their use should be part of a treatment conversation that includes a plan for how long they'll be used, what the monitoring looks like, and what behavioral strategies are happening alongside the medication. Chronic hypnotic use without a behavioral framework is not best-practice sleep psychiatry.
Trazodone, mirtazapine, and quetiapine are also frequently used off-label for insomnia; all have sedating properties and are not scheduled. Their use is clinically rational in contexts where there's a comorbid depression or anxiety indication, but they each carry their own side effect profiles that should be discussed.
The telehealth approach to insomnia and mental health
When a patient presents to a telehealth psychiatrist with both a mood or anxiety disorder and significant sleep disruption, a thoughtful clinician will address both components of the picture rather than assuming one will resolve automatically when the other is treated. This might look like starting an SSRI for depression while also initiating a referral to a CBT-I program and adding a low-dose sleep aid for the short term to reduce the acute burden of sleep deprivation that makes depression harder to treat.
Sleep itself can be tracked meaningfully without expensive equipment. Most smartphones provide basic sleep tracking through their health apps; wearables offer more detailed data on sleep stages. While consumer-grade sleep tracking shouldn't be over-interpreted as diagnostic data, a simple log of time in bed, estimated sleep onset, and wake time — kept for two weeks before a psychiatry appointment — gives your provider more useful information than a verbal estimate of "I sleep badly."
A useful framing: think of sleep less as a symptom to be managed and more as a physiological foundation that other mental health interventions depend on. Antidepressants work better in patients who are sleeping. CBT for anxiety works better when cognitive processes aren't degraded by sleep deprivation. This doesn't mean you need perfect sleep before other treatments begin — it means that addressing sleep as a primary target, rather than always a secondary one, often accelerates the overall trajectory of care.